Clinical data
AHFS/ International Drug Names
MedlinePlus a605022
  • US: D (Evidence of risk)
Routes of
By mouth (tablets)
ATC code N03AA01 (WHO)
Legal status
Legal status
Pharmacokinetic data
Protein binding 70–76%
Metabolism Liver
Biological half-life 34 hours
CAS Number 115-38-8 YesY
PubChem (CID) 8271
DrugBank DB00849 YesY
ChemSpider 7972 YesY
KEGG D00700 YesY
ECHA InfoCard 100.003.714
Chemical and physical data
Formula C13H14N2O3
Molar mass 246.3 g/mol
3D model (Jmol) Interactive image

Methylphenobarbital (INN), also known as mephobarbital (USAN, JAN) and mephobarbitone (BAN), marketed under brand names such as Mebaral, Mephyltaletten, Phemiton, and Prominal, is a drug which is a barbiturate derivative and is used primarily as an anticonvulsant,[1] but also as a sedative and anxiolytic. It is the N-methylated analogue of phenobarbital and has similar indications, therapeutic value, and tolerability.

Approval history

The company further stated in a letter on its website [2] that under the FDA's Unapproved Drugs Initiative, FDA is no longer willing to allow the drug to be grandfathered. A new drug application would have needed to have been submitted to gain marketing approval, which would have taken an estimated five years, during which time patients would be required to change their therapies in any case. The last available tablets bore an expiration date of March 31, 2012, and the drug will no longer be available in the US when supplies are depleted.


Symptoms of overdose of mephobarbital include confusion, decrease in or loss of reflexes, somnolence, fever, irritability, hypothermia, poor judgment, shortness of breath or slow/troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness.

See also


  1. S. D. Shorvon; David R. Fish; Emilio Perucca; W. Edwin Dodson, eds. (2004). The Treatment of Epilepsy (2nd ed.). Blackwell. ISBN 0-632-06046-8.
  2. Letter from Lundbeck to prescribers
This article is issued from Wikipedia - version of the 9/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.